Thomas J. O'Hare, PhD

Research Interests

  • Design and Synthesis of Targeted Cancer Drugs
  • Tyrosine Kinase Activating Mutations
  • Leukemia, Myeloid, Philadelphia-Positive
  • Drug Resistance

Labs

Lab Website

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Research Professor
  • Divisions: Hematology/BMT
  • Cancer Center Programs: Cell Response & Regulation

Academic Office Information

  • 801-585-0256
  • Huntsman Cancer Institute
    HCI4264
    2000 Circle of Hope, Room: HCI 4264
    Salt Lake City, UT 84112

Academic Bio

Thomas J. O'Hare, Ph.D. is a Research Professor of Medicine (career track) in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah. His lab is located in the Huntsman Cancer Institute and he is a member of the Cell Response and Regulation Program. He received his B.Sc. in Chemistry from Southern Oregon University in Ashland, followed by his Ph.D. in Chemistry at the University of Washington in Seattle. Dr. O'Hare completed two Postdoctoral Fellowships: one in Chemistry at Oregon State University and one in Molecular Microbiology and Immunology at Oregon Health & Science University in Portland.

Dr. O'Hare's research focuses on Chronic Myeloid Leukemia, Acute Myeloid Leukemia and other blood cancers. He also has a research interest in non-small cell lung cancer driven by misregulated fusion kinases such as ROS1.

Education History

Type School Degree
Postdoctoral Fellowship Oregon Health & Science University
Molecular Microbiology and Immunology
Postdoctoral Fellow
Postdoctoral Fellowship Oregon State University
Chemistry
Postdoctoral Fellow
Doctoral Training University of Washington
Chemistry
Ph.D.
Undergraduate Southern Oregon University
Chemistry
B.Sc.

Selected Publications

Journal Article

  1. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. (Epub ahead of print) Leukemia.
  2. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398.
  3. Yan D, Pomicter AD, OHare T, Deininger MW (2019). ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation? Clin Cancer Res, 25(22), 6561-6563.
  4. Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, Ahmann JM, OHare T, Deininger MW (2019). The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv, 3(20), 2949-2961.
  5. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, OHare T, Druker BJ, Deininger MW (2019). Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell, 36(4), 431-443.e5.
  6. Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, OHare T (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol, 77, 36-40.e2.
  7. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, OHare T, Deininger MW (2018). Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res, 25(7), 2323-2335.
  8. Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, OHare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT (2019). Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem, 62(5), 2651-2665.

Video